Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Inclusion Criteria: * documentation of a diagnosis of active acromegaly based on either of the following definitions: 1. the patient has never received somatostatin analog nor dopaminergic agonist or had previously received this medication but had stopped more than 3 months before visit 1 and had a mean growth hormone (GH)level \>5ng/mL at visit 1; or 2. the patient was receiving treatment with a somatostatin analog (other than lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean GH \>3ng/mL at visit 2 (or visit 2a) and had at least a 100% increase in mean GH levels between visit 1 and visit 2 (or visit 2a) Exclusion Criteria: * receipt of radiotherapy for acromegaly within 3 years * pituitary surgery within 3 months prior to visit 1 * prior receipt of lanreotide autogel or GH antagonist * anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study period * known hypersensitivity to any of the test materials or related compounds * clinically significant renal or hepatic abnormalities